Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | TYMS | P04818 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 3/20 | 0.51 |
| ▸ | MMP9 | P14780 | 3/20 | 0.51 |
| ▸ | MMP8 | P22894 | 3/20 | 0.51 |
| ▸ | MMP13 | P45452 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31473884 | 1.00 | ALDH1A1 (0.61) | ALDH1A1TYMSRAB9ALMNAHSP90AA1 | |
| SCHEMBL8982 | 0.84 | TYMS (0.49) | ALDH1A1TYMSRAB9ALMNAHSP90AA1 | |
| SCHEMBL2457137 | 0.79 | RAB9A (0.67) | ALDH1A1RAB9AHSP90AA1ESR2TDP1 | |
| SCHEMBL29727934 | 0.79 | ALDH1A1 (0.66) | ALDH1A1RAB9AHSP90AA1ESR2TDP1 | |
| SCHEMBL266609 | 0.79 | ALDH1A1 (0.66) | ALDH1A1RAB9AHSP90AA1ESR2TDP1 | |
| SCHEMBL14474322 | 0.78 | ALDH1A1 (0.54) | ALDH1A1TYMSRAB9ALMNAMAPT | |
| SCHEMBL7590755 | 0.76 | ALDH1A1 (0.61) | ALDH1A1TYMSRAB9AHSP90AA1ESR2 | |
| SCHEMBL1405837 | 0.76 | ALDH1A1 (0.61) | ALDH1A1RAB9AHSP90AA1ESR2TDP1 | |
| SCHEMBL1925827 | 0.76 | MAPT (0.76) | ALDH1A1RAB9AHSP90AA1ESR2TDP1 | |
| SCHEMBL8290000 | 0.76 | ALDH1A1 (0.61) | ALDH1A1TYMSRAB9AHSP90AA1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119425419-A | Metal-organic framework composite membrane for helium and methane mixed gas separation and preparation method and application thereof | 苏州大学 | 2025-02-14 | — | — | CN | claimed |
| CN-120424484-A | Scratch-resistant high-transparency polycarbonate with self-repairing function and preparation method thereof | 青岛国恩科技股份有限公司 | 2025-08-05 | — | — | CN | disclosed |
| WO-2025122822-A1 | THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119730846-A | Kinase modulators and methods of use thereof | 神经元23公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119425419-A | Metal-organic framework composite membrane for helium and methane mixed gas separation and preparation method and application thereof | 苏州大学 | 2025-02-14 | — | — | CN | disclosed |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| WO-2023244788-A9 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| WO-2024044757-A1 | AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044757-A1 | AMINOPYRIMIDINE AND AMINOTRIAZINE DERIVATIVES AS MYC PROTEIN MODULATORS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2010135568-A1 | BENZOXAZEPINES AS INHIBITORS OF MTOR AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
| WO-2009118292-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
| EP-2090577-A2 | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | Signal Pharmaceuticals LLC (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-2078016-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-01-22 | — | — | US | disclosed |
| WO-2008051493-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | ALDH1A1 3395/4885TYMS 3147/4885RAB9A 1023/4885 |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | ALDH1A1 4305/4885TYMS 3171/4885RAB9A 1297/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | ALDH1A1 1694/4885TYMS 588/4885RAB9A 3263/4885 |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, PHKG1, PHKG2 | ALDH1A1 1934/4885TYMS 1638/4885RAB9A 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.